A 50-year-old woman was admitted to hospital due to fevers, dyspnea and hematuria. She was in second remission at 3 months post allogeneic stem cell transplant for AML from a matched unrelated donor. Her conditioning regimen consisted of fludarabine, busulfan and 400 cGy total body radiation. GvHD prophylaxis consisted of antithymocyte globulin, 2 doses of posttransplant cyclophosphamide and cyclosporine. She had a prior history of campath-and fludarabine-use 3 months prior to transplantation. Pretransplant comorbidities included hypertension and hepatitis B core Ab positivity. Her early post-transplant course was complicated by CMV reactivation, Hickman exit site infection by Staphylococcus aureus, drug-induced pancytopenia and BK-virus-associated hemorrhagic cystitis.
She presented to the outpatient clinic with fatigue and fevers up to 38°C with macroscopic hematuria with evidence of clots. Cardiac, respiratory and abdominal exams were unremarkable. She was admitted for further management of her hematuria and workup of fevers, and was empirically started on antibiotics and antifungal agents. Computed tomography of the chest was done for respiratory distress 6 days later, which revealed small bilateral pleural effusions and left upper lobe peribronchovascular consolidation with mediastinal and hilar lymphadenopathy. Similar adenopathy was evident on abdominal scanning. Diagnostic bronchoscopy performed for microbiological cultures was negative, including mycobacterial cultures.
She continued to have worsening respiratory distress and developed small reddish colored lesions on her head, neck, chest, arms and legs 10 days after admission ( Figure 1 ). Skin biopsy performed was positive for Mycobacterium tuberculosis, which was stained by Ziehl-Neelsen staining and on culture. She was initiated on isoniazid, rifampin, ethambutol and moxifloxacin after consultation with the infectious disease specialists. No positive family history for tuberculosis or its exposure could be elicited. Retrospectively, it was elucidated that she worked as a physician involved in the care of prison inmates with active tuberculosis in Eastern Europe. Further investigations for mycobacterial dissemination including bone marrow and thoracentesis were negative. After 1 month of antimycobacterial treatment, she showed significant interval improvement clinically and radiologically in terms of the lymphadenopathy, pleural effusions and pulmonary consolidations. She was successfully discharged and continued to follow up with further improvement to complete a total 9 months of antitubercular treatment.
Tuberculosis infection continues to be a significant public health issue, with over 9 million new cases in 2014 according to the World Health Organization (WHO). 1 The rate of tuberculosis infection among hematopoietic transplant patients ranges from 0.0014 to 3% in US studies, however, it can be as high as 16% in endemic areas. 2 Miliary tuberculosis is an uncommon subtype, resulting from dissemination of pulmonary infection. Previously mostly seen in children, it is now increasingly recognized in the adult population with immunosuppression such as HIV, organ transplantation and immunosuppressive medications. In a review of 25 studies by Russo et al., 2 out of 113 tuberculosis cases, 12 were disseminated. A 10-year retrospective review in an endemic area also found a low proportion of extrapulmonary manifestations (5 compared with 34 pulmonary involvement alone). 3 Risk factors for tuberculosis infection identified in the literature include T-cell depletion, matched unrelated donors, use of steroids, conditioning regimens and underlying malignancy. 4 Making the diagnosis can be difficult in a post allogeneic stem cell transplant patient due to the atypical clinical manifestations including fever of unknown origin, acute respiratory distress syndrome, acute kidney injury and cholestatic jaundice. This delay places patients at higher risk of mortality, which has been reported to be 25-30%. 5 On review of the literature of disseminated cases of tuberculosis in stem cell transplant patients, diagnosis was usually made from bronchial lavage or bone marrow biopsy [6] [7] [8] [9] [10] [11] (Table 1) . There was one case who had skin biopsy confirming cutaneous involvement in addition to previously established disease. 7 This case report is unique as the diagnosis was confirmed only from skin biopsy, despite a number of investigations performed to find the site of origin of infection. This report is presented here to make the clinician aware of this distinct clinical entity in the differential diagnosis of posttransplant recipients presenting with respiratory distress, adenopathy and pleural effusions.
There is no standardized therapy for tuberculosis treatment in the context of hematopoietic stem cell transplantation. The WHO Guidelines recommend that patients living with HIV should have at least the same duration of tuberculosis treatment as HIVnegative patients, 12 though some experts may recommend extended treatment in certain circumstances. 11 Standard treatment involves 2 months of isoniazid, rifampicin, pyrazinamide and ethambutol, followed by 4 months of isoniazid and rifampicin. In summary, miliary tuberculosis is an uncommon but life threatening form of tuberculosis. Bone marrow transplant patients are at significant high risk due to their immunocompromised state either because of delayed immune reconstitution or use of immunosuppressive medication used for treatment of GvHD. Early recognition and prompt treatment are key to good outcomes in this patient population. Further studies are needed to determine the characteristics of tuberculosis infection in the context of hematopoietic stem cell transplant. 
